Hikma Pharmaceuticals Share News (HIK)

LONDON BROKER RATINGS: Trio of downgrades for Fevertree; Admiral cut

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

LONDON BROKER RATINGS: Jefferies likes Tyman; UBS cuts Beazley

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

LONDON BROKER RATINGS: JPMorgan cuts Hikma; Liberum likes Trustpilot

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

LONDON BRIEFING: M&S warns on cost hit to profit but is well placed

(Alliance News) - Marks & Spencer on Wednesday reported a swing to profit for the year ended April 2, but the clothing, homewares and food retailer cautioned on profit in the year ahead, amid the war in Ukraine and investment plans.

IN BRIEF: Hikma Pharmaceuticals Chief Executive Siggi Olafsson resigns

Hikma Pharmaceuticals PLC - London-based pharmaceutical company - Says Siggi Olafsson has resigned as chief executive officer and from the board to "pursue other opportunities." Adds he will remain available to the company until he resigns on June 24. Olafsson was appointed as CEO in 2018. Before he joined Hikma, he was president of peer firm Actavis Generics until 2014 from 2012.

LONDON BRIEFING: Barclays launches delayed GBP1 billion share buyback

(Alliance News) - Barclays said it will kick off a GBP1.00 billion share buyback programme on Tuesday. The programme, initially announced in February, had been delayed in March after the bank admitted it sold more financial products to investors than it was allowed to.

Hikma's Siggi Olafsson stands down as CEO

(Sharecast News) - Drugmaker Hikma Pharmaceuticals revealed on Tuesday that chief executive Siggi Olafsson has resigned from both the role and the company's board of directors in order to pursue other opportunities.

UK shareholder meetings calendar - next 7 days

LONDON BROKER RATINGS: Downgrades for Centrica and Rathbones

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

LONDON MARKET MIDDAY: Pound slips as BoE opts for quarter-point hike

(Alliance News) - Stock prices in London were higher, while the pound was flat, on Thursday, after the Bank of England as expected raised UK interest rates by a quarter percentage point.

Signs of slowdown on the continent

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com

SIGNS OF SLOWDOWN ON THE CONTINENT (1051 GMT)

TOP NEWS: Hikma shares fall 10% on delay to Jazz Pharmaceuticals drug

(Alliance News) - Shares in Hikma Pharmaceuticals PLC fell early Thursday, after the drugmaker downgraded guidance for its Generics business due to the delayed launch of a generic of the Xyrem treatment for narcolepsy.

LONDON MARKET OPEN: Mondi and Shell lift FTSE 100 after strong updates

(Alliance News) - Stock prices in London opened sharply higher on Thursday after the US Federal reserve assuaged fears over further aggressive monetary policy tightening, while positive updates from Mondi and Shell boosted the FTSE 100.

Hikma cuts 2022 generics guidance due to drug launch delay

(Sharecast News) - Hikma Pharmaceuticals cut guidance for its generics business on Thursday, citing a delay to a drug launch.

IN BRIEF: Hikma says has not entered license agreement with Opiant

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Confirms that it has not entered into any transaction with Opiant Pharmaceutical UK, following a PR Newswire announcement issued on Friday. The release said Opiant and Hikma entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.